Business
aTyr Pharma Announces First Major Review Article for Efzofitimod Published in the Journal Sarcoidosis, Vasculitis and Diffuse Lung Diseases
Paper highlights efzofitimod as a first-in-class biologic with significant anti-inflammatory properties SAN DIEGO, March 30, 2023 (GLOBE NEWSWIRE) -- aTyr
About this update from Atyr Pharma, Inc.
[{"type":"text","content":"Paper highlights efzofitimod as a first-in-class biologic with significant anti-inflammatory properties\nSAN DIEGO, March 30, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced the publication of a review article, titled, “Efzofitimod: a novel anti-inflammatory agent for sarcoidosis,” in the peer-reviewed journal Sarcoidosis, Vasculitis and Diffuse Lung Diseases. The publication is available on the journal’s website and at: https://doi.org/10.36141/svdld.v40i1.14396. In the paper, the authors, led by Robert P. Baughman, M.D., Professor of Medicine at the University of Cincinnati Medical Center, describe the mechanism for efzofitimod as it relates to the granulomatous inflammation central to the pathophysiology of sarcoidosis, including the role of its binding partner neuropilin-2 (NRP2), a cell surface receptor that is highly expressed in sarcoid granulomas. The authors also review the preclinical and clinical data generated for efzofitimod that support its anti-inflammatory properties and the potential for it to be a novel therapeutic approach to immune-mediated fibrotic lung diseases such as pulmonary sarcoidosis. “This publication highlights efzofitimod as a first-in-class biologic for the treatment of sarcoidosis based on a review of the evolving mechanistic understanding of this novel immunomodulator and the clinical data generated in pulmonary sarcoidosis patients,” said Dr. Baughman. “Oral corticosteroids remain the cornerstone of treatment for symptomatic sarcoidosis, but long-term treatment often comes with significant side effects and reduced quality of life. A treatment such as efzofitimod, which may reduce steroid burden while improving lung function and quality of life measures, is greatly needed—and long overdue— for patients with this disease.” “This first-ever review recognizes the potential of efzofitimod to be a transformative therapy for patients with pulmonary sarcoidosis,” said Sanjay S. Shukla, M.D., M.S., President and CEO of aTyr. “EFZO-FIT™ is the first Phase 3 interventional study to be conducted in pulmonary sarcoidosis and is currently enrolling patients at multiple centers in the U.S, Europe and Japan. We believe this study presents a la...